Abstract | BACKGROUND: METHODS: RESULTS: The operative complications of the 2 groups were not significantly different (P=0.753). The radioactivity ratio of the tumor to the liver was approximately 4.1:1 for the 131I-DEM TACE group. In the 131I-DEM TACE group, 54.5% of patients achieved tumor regression of more than 50%, compared to 36.6% of patients in the cTACE group. AFP levels in serum declined in 100% of patients in the 131I-DEM TACE group and 50% of patients in the cTACE group. The median survival time of the patients was 12.0±3.3 months for the 131I-DEM TACE group and 10.0±3.3 months for the cTACE group. There were no significant differences in survival between the 2 groups (P=0.414). CONCLUSIONS: 131I-DEM may become a potential radiochemoembolization agent to treat patients with unresectable hepatocellular carcinoma through TACE.
|
Authors | Yu Ma, Ligeng Duan, Lin Li, Wusheng Lu, Bo Li, Xiaoli Chen |
Journal | Journal of gastrointestinal oncology
(J Gastrointest Oncol)
Vol. 12
Issue 2
Pg. 762-769
(Apr 2021)
ISSN: 2078-6891 [Print] China |
PMID | 34012664
(Publication Type: Journal Article)
|
Copyright | 2021 Journal of Gastrointestinal Oncology. All rights reserved. |